Efficacy and Safety of Apatinib plus Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cancer: A Phase II Trial

Table 2

Incidence of adverse events during neoadjuvant treatment.

Adverse events	Any grade, (%)	Grades 3/4, (%)
Hematological
Leukopenia	21 (53.8)	6 (15.3)
Neutropenia	20 (51.2)	6 (15.3)
Anemia	16 (41.0)	2 (5.1)
Thrombocytopenia	5 (12.8)	1 (2.5)
Nonhematological
Hypertension	10 (25.6)	4 (10.2)
Proteinuria	3 (7.6)	1 (2.5)
Hand-foot syndrome	1 (2.5)	0 (%)
Aminotransferase increased	2 (5.1)	1 (2.5)
Hyperbilirubinemia	1 (2.5)	0 (0)
Naupathia	30 (76.9)	5 (12.8)
Vomiting	20 (51.2)	5 (12.8)
Stomachache	1 (2.5)	0 (0)